HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter A Jones Selected Research

Decitabine

1/2023RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer.
10/2021Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
10/2018Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells.
1/2016Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine.
4/2013Functional DNA demethylation is accompanied by chromatin accessibility.
1/2012Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions.
4/2011Epigenetic reprogramming as a key contributor to melanocyte malignant transformation.
7/2007Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides.
1/2007Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment.
5/2005Discovery of epigenetically masked tumor suppressor genes in endometrial cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peter A Jones Research Topics

Disease

69Neoplasms (Cancer)
02/2024 - 02/2002
8Carcinogenesis
01/2019 - 10/2005
8Breast Neoplasms (Breast Cancer)
06/2017 - 06/2004
7Myelodysplastic Syndromes (Myelodysplastic Syndrome)
04/2013 - 10/2002
7Urinary Bladder Neoplasms (Bladder Cancer)
02/2009 - 02/2002
5Carcinoma (Carcinomatosis)
01/2023 - 04/2002
5Hematologic Neoplasms (Hematological Malignancy)
10/2021 - 06/2009
4Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 04/2013
4Prostatic Neoplasms (Prostate Cancer)
12/2017 - 10/2006
4Transitional Cell Carcinoma
09/2010 - 10/2005
3Testicular Neoplasms (Testicular Cancer)
01/2019 - 09/2010
3Melanoma (Melanoma, Malignant)
11/2011 - 12/2009
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2023 - 11/2013
2Polyps
07/2022 - 09/2008
2Colonic Neoplasms (Colon Cancer)
01/2022 - 04/2015
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2021 - 09/2010
2Ascorbic Acid Deficiency (Vitamin C Deficiency)
10/2019 - 01/2016
1Adenocarcinoma of Lung
07/2023
1Kidney Neoplasms (Kidney Cancer)
01/2023
1Hepatocellular Carcinoma (Hepatoma)
11/2022
1Chronic Obstructive Pulmonary Disease (COPD)
01/2022
1Ovarian Neoplasms (Ovarian Cancer)
10/2018
1Endometriosis
10/2017
1Triple Negative Breast Neoplasms
06/2017
1Lymphoma (Lymphomas)
09/2016
1Renal Cell Carcinoma (Grawitz Tumor)
01/2016
1Leukemia
02/2014
1Cystitis
07/2013
1Inflammation (Inflammations)
07/2013
1Disease Progression
12/2012
1Neoplasm Metastasis (Metastasis)
02/2009

Drug/Important Bio-Agent (IBA)

28DNA (Deoxyribonucleic Acid)IBA
01/2023 - 06/2002
15ChromatinIBA
01/2023 - 06/2002
14DecitabineFDA Link
01/2023 - 02/2002
13MethyltransferasesIBA
11/2022 - 08/2003
9Histones (Histone)IBA
10/2018 - 11/2002
7Nucleosomes (Nucleosome)IBA
01/2017 - 01/2010
7MicroRNAs (MicroRNA)IBA
04/2011 - 06/2006
6Azacitidine (5 Azacytidine)FDA Link
10/2021 - 09/2010
6pyrimidin-2-one beta-ribofuranosideIBA
09/2008 - 03/2003
5Lysine (L-Lysine)FDA Link
10/2018 - 11/2002
5CytosineIBA
01/2018 - 11/2002
4A-Form DNA (A-DNA)IBA
01/2022 - 04/2015
4AntigensIBA
01/2019 - 08/2004
4Histone Deacetylase InhibitorsIBA
06/2017 - 05/2005
4EnzymesIBA
01/2016 - 05/2004
3RNA (Ribonucleic Acid)IBA
01/2023 - 09/2010
3Ascorbic Acid (Vitamin C)FDA LinkGeneric
10/2019 - 01/2016
3Hormones (Hormone)IBA
06/2017 - 06/2004
2InterferonsIBA
07/2023 - 02/2014
2DNA Transposable Elements (Element, IS)IBA
01/2023 - 01/2019
2Histone MethyltransferasesIBA
01/2023 - 10/2018
2LigandsIBA
01/2023 - 12/2011
25-Methylcytosine (5 Methylcytosine)IBA
10/2019 - 01/2011
2Estrogen ReceptorsIBA
06/2017 - 02/2014
2entinostat (MS 275)IBA
06/2017 - 05/2017
2Proteins (Proteins, Gene)FDA Link
02/2014 - 12/2007
2Androgen Receptors (Androgen Receptor)IBA
12/2011 - 10/2006
2MART-1 AntigenIBA
04/2011 - 12/2009
2Polycomb-Group ProteinsIBA
08/2009 - 03/2009
2OligonucleotidesIBA
07/2007 - 02/2002
2Histone Deacetylases (Histone Deacetylase)IBA
06/2006 - 05/2004
2Tumor Suppressor Protein p14ARF (p14ARF)IBA
11/2005 - 11/2002
2polyurethane-polypropylene composite (TMS 1)IBA
11/2005 - 11/2004
2Antineoplastic Agents (Antineoplastics)IBA
11/2005 - 01/2005
1UbiquitinIBA
02/2024
1guadecitabineIBA
01/2023
1Immune Checkpoint InhibitorsIBA
01/2023
1atezolizumabIBA
01/2023
1GSK-2816126IBA
11/2022
1Transcription Factor AP-1 (Transcription Factor AP 1)IBA
07/2022
1CytidineIBA
10/2021
1DeoxyguanosineIBA
10/2019
15-hydroxymethylcytosineIBA
10/2019
1Antiviral Agents (Antivirals)IBA
10/2018
1PaxillinIBA
10/2017
1CollagenIBA
10/2017
1IntegrinsIBA
10/2017
1Transcription Factors (Transcription Factor)IBA
09/2014
1Genetic Markers (Genetic Marker)IBA
04/2014
1ChemokinesIBA
02/2014
1CytokinesIBA
02/2014
1Estrogens (Estrogen)FDA Link
02/2014
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2013
1Coloring Agents (Dyes)IBA
06/2013
1VorinostatFDA Link
04/2013
1trichostatin A (A 300)IBA
04/2011
1SuspensionsIBA
12/2009
13-deazaneplanocinIBA
06/2009
1Polycomb Repressive Complex 2IBA
03/2009

Therapy/Procedure

28Therapeutics
07/2023 - 05/2004
5Aftercare (After-Treatment)
01/2023 - 05/2005
4Drug Therapy (Chemotherapy)
12/2008 - 01/2005
3Immunotherapy
07/2023 - 01/2019
3Oral Administration
09/2008 - 01/2005
2Microbubbles
08/2012 - 02/2011
1Investigational Therapies (Experimental Therapy)
11/2013
1Injections
07/2013
1Segmental Mastectomy (Lumpectomy)
06/2013
1Intradermal Injections
02/2011